- Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results
- Soligenix Announces Formation of Behçet's Disease Medical Advisory Board
- Soligenix to Present at The Microcap Conference
- FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease
- Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
- Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses
More ▼
Key statistics
On Wednesday, Soligenix Inc (SNGX:NAQ) closed at 0.6071, 59.76% above the 52 week low of 0.38 set on Nov 16, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.600 |
---|---|
High | 0.6119 |
Low | 0.600 |
Bid | 0.50 |
Offer | 0.62 |
Previous close | 0.6071 |
Average volume | 85.69k |
---|---|
Shares outstanding | 10.52m |
Free float | 10.51m |
P/E (TTM) | -- |
Market cap | 6.39m USD |
EPS (TTM) | -0.9164 USD |
Data delayed at least 15 minutes, as of Mar 27 2024 20:00 BST.
More ▼